论文部分内容阅读
目的观察阿托伐他汀联合曲美他嗪治疗冠心病(CHD)的临床疗效。方法选择2014年10月—2015年12月西安医学院附属西安市北方医院心内科收治的CHD患者114例,根据入院顺序分为对照组和观察组,每组57例。两组患者入院后均给予常规治疗,对照组患者在常规治疗基础上口服曲美他嗪,观察组患者在常规治疗基础上口服曲美他嗪和阿托伐他汀;两组患者均连续治疗4周。比较两组患者临床疗效、治疗前后血清炎性因子水平及血脂指标、不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前两组患者血清C反应蛋白(CRP)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清CRP、TC、TG、LDL-C水平低于对照组,血清HDL-C水平高于对照组,差异有统计学意义(P<0.05)。治疗后观察组患者血清CRP、TC、TG、LDL-C水平低于治疗前,血清HDL-C水平高于治疗前(P<0.05);治疗后对照组患者血清CRP、TC、LDL-C水平低于治疗前(P<0.05),而血清TG、HDL-C水平与治疗前比较,差异无统计学意义(P>0.05)。治疗期间两组患者均未出现明显不良反应。结论阿托伐他汀联合曲美他嗪联合治疗CHD的临床疗效确切,可有效改善患者血脂指标、减轻炎性反应。
Objective To observe the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of coronary heart disease (CHD). Methods From October 2014 to December 2015, 114 CHD patients admitted to Department of Cardiology, Xi’an North Hospital Affiliated to Xi’an Medical College were divided into control group and observation group, 57 cases in each group. Both groups were given routine treatment after admission. Patients in the control group were given trimetazidine orally on the basis of routine treatment. Patients in the observation group were given trimetazidine and atorvastatin on the basis of routine treatment. Both groups were treated 4 week. The clinical curative effect, the levels of serum inflammatory cytokines, blood lipid index and adverse reactions before and after treatment were compared between the two groups. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). The levels of serum C-reactive protein (CRP), total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL- (P> 0.05). After treatment, the levels of serum CRP, TC, TG and LDL-C in the observation group were lower than those in the control group, and the serum HDL-C levels were significantly higher than those in the control group (P < 0.05). After treatment, the levels of serum CRP, TC, TG and LDL-C in the observation group were lower than those before treatment (P <0.05), and the levels of CRP, TC and LDL-C in the control group (P <0.05), while the serum levels of TG and HDL-C were not significantly different from those before treatment (P> 0.05). No significant adverse reactions occurred in both groups during treatment. Conclusion Atorvastatin combined with trimetazidine combined treatment of CHD clinical curative effect is exact, can effectively improve the patient’s lipid profile, reduce the inflammatory response.